We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Dennis Thomas M.Pharm, PhD

Dennis Thomas M.Pharm, PhD

Postdoctoral Research Fellow, Priority Research Centre for Healthy Lungs, College of Health, Medicine and Wellbeing, University of Newcastle, Hunter Medical Research Institute, Newcastle, Australia

Dr. Thomas is a Postdoctoral Research Fellow at the Hunter Medical Research Institute, The University of Newcastle, Australia. He is currently involved in the design and implementation of various telehealth-based, point-of-care clinical trials in the area of respiratory medicine.

His prior appointment was a Project Coordinator/Postdoctoral Research Fellow at the National Drug and Alcohol Research Centre, The University of New South Wales, where he worked on Australia’s largest (n=1,452), telehealth-based, phase-3, smoking cessation RCT comparing the cost-effectiveness of two smoking cessation medications.

He completed his PhD from the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University. Prior to the PhD, Dr Thomas obtained his Bachelor’s and Master’s degrees in Pharmacy from Rajiv Gandhi University of Health Sciences, Bangalore, India. Then he worked for a pharmaceutical company as a Clinical Trial Manager, designing and conducting clinical trials in different therapeutic areas. His research interests include telehealth RCTs, technology-based interventions and safety/efficacy of pharmaceuticals.


Dr. Thomas has no relevant disclosures.

Recent Contributions to PracticeUpdate:

  1. Efficacy of Gefapixant in the Treatment of Chronic Cough